Childhood-Onset Growth Hormone Deficiency

jarmoluk / Pixabay

Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment

Post author:Rose Duesterwald
Post published:May 12, 2022
Post category:Growth hormone deficiency

Aeterna Zentaris’s ongoing DETECT trial is evaluating the drug macimorelin (tradename Macrilen™) for childhood-onset growth hormone deficiency (CGHD). As recently announced in an article published by GlobeNewsWire, the study (AEZS-130-PO2),…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More